Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spectral takes EAA to Japan through Toray partnership:

This article was originally published in Clinica

Executive Summary

Spectral Diagnostics has expanded its partnership with Toray Medical by appointing it as exclusive distributor of the EAA test for sepsis risk. Tokyo-headquartered Toray will market and sell Spectral's EAA system as a stand-alone product and also in conjunction with its own Toraymyxin blood purification device. The two companies have been partners over the last three years to research the use of EAA together with Toraymyxin products. Toronto, Ontario-based Spectral said that the deal will also provide it with access to other Asian countries - Toray is established in China, Indonesia, Korea, Singapore and Thailand, as well as Japan. In addition to the Toray alliance, Spectral boosted its presence in the European market this year, by signing deals with Menarini and Estor to distribute the EAA system in Germany and Italy, respectively.

You may also be interested in...

Zur Rose Calls For Swiss Online Liberalization To Manage Coronavirus OTC Demand

Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.

UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts